AnthonyL.B.: Long acting formulation of somatostatin analogues. Ital. J. Gastroenterol. Hepatol., 31(Suppl. 2): S216–S218, 1999.
2.
BombardieriE., ChitiA., CrippaF., SeregniE., CataldoI., MaffioliL., SoresiE.: 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer. Q. J. Nucl. Med., 39(suppl. 1): S104–S107, 1995.
3.
KwekkeboomD.J., LambertsS.W., HabbemaJ.D., KrenningE.P.: Cost-effectiveness analysis of somatostatin receptor scintigraphy. J. Nucl. Med., 37: 886–892, 1996.
4.
RicciS., AntonuzzoA., GalliL., FerdeghiniM., BodeiL., OrlandiniC., ConteP.F.: Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann. Oncol., submitted for publication.
5.
RubinJ., AjaniJ., SchirmerW., VenookA.P., BukowskiR.: Octreotide acetate long-acting formulation versus open label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol., 17: 600–606, 1999.
